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immune surveillance seemed antiviral and 
not antitumoral, and despite the discovery 
of tumor-associated antigens in the 1990s, 
cancer immunotherapy yielded scarce suc-
cesses. With the exception of Interleukin-2 
for the treatment of metastatic renal cell 
cancer, no immunotherapeutic drugs have 
been approved. Accordingly, with the recent 
triumphant march of cancer genomics, and 
the discovery of targeted chemotherapies, 
cancer immunology has been consigned to 
the dark once again.
However, the beginning of the twenty-
first century witnessed a renaissance of 
the field. Basic studies demonstrated that 
tumors develop more easily and rapidly 
in immunodeficient animals, even with-
out oncogene activation or chemical pro-
motion. Clinical studies established that, 
whereas chronic inflammation promotes 
cancer growth and metastasis, intratu-
moral Th1/CD8 memory T cell infiltration 
is a major prognostic factor for disease-
free as well as overall survival in cancer 
patients. Even more practically important, 
efficient immunotherapies mostly based 
on the use of monoclonal antibodies tar-
geted to the tumor cells or modulating 
the immune and stromal status, are being 
approved, which has changed the manage-
ment of many cancers. A first therapeutic 
vaccine, using antigen-pulsed dendritic 
cells, has become a new treatment modal-
ity for metastatic prostatic cancer; others 
will come. In this regard, it is noteworthy 
that the efficacy of classical treatments, 
such as chemotherapies, seems to depend 
on their capacity to activate an anti-tumor 
immune reaction.
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The twentieth century has been a time of 
intense debate on the role of the immune 
system in controlling cancer initiation, 
growth, and final victory.
At the beginning of the century, accord-
ing to the common sense generated by the 
very recent Pasteur discoveries, physicians 
and scientists have considered a growing 
cancer as an internal infection involving 
a fight with the patient’s immune system. 
They were so convinced of the similarities 
between cancer and infections that William 
B. Coley proposed to treat patients with 
bacterial toxins, hypothesizing that the 
anti-bacterial immune response would 
clear the tumor. Although infrequent but 
undisputable therapeutic successes of 
this approach, together with epidemio-
logic studies reporting high incidence of 
cancer in immunodeficient individuals, 
yielded to the launching of the theory of 
immunosurveillance of cancer in the late 
1950s. This theory proposed that, as for 
infectious agents, nascent cancerous cells, 
although originating from self, bore neo-
antigens recognized by the host’s immune 
system and are therefore in most cases 
rejected. Only in immuno-impaired indi-
viduals (primary or induced by viruses or 
chemicals) or when developing in immu-
noprivileged sites, would cancers grow, 
become clinically detectable and kill the 
patient despite the efforts of his immune 
system, i.e., a family story inside the body, 
very badly controlled, finishing in a very 
unhappy ending. Contenders of this the-
ory were however numerous. Most cancers 
originating in immunodeficient individu-
als were found to be of viral origin, so that 
Even so, major questions have not yet 
been resolved, among which are: Is an 
immune reaction efficient because it rec-
ognizes cancer cell antigens or because it 
modifies the tumor microenvironment? 
How do the cancer cells and the plastic-
ity of their genome influence the immune 
contexture? What tumor-associated driver 
molecules should be targeted by immu-
notherapies? What is the complexity of 
the tumor-associated immune reaction 
in terms of immune cell populations and 
targets, how is it modified during tumor 
evolution, and how is it in primary sites 
compared with different metastatic sites? 
Should all efficient therapies modulate the 
immune reaction and how?
The era of large libraries of human speci-
mens linked to systems biology and tailored 
mouse models will allow us to address these 
questions in an effective manner, and to 
propose an immunological management 
of the diseases, taking place in the grow-
ing field of targeted therapies based on the 
cancerous cells but also on the genetics of 
the patient, as well as the environment of 
the tumor cells.
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